Table of Contents Author Guidelines Submit a Manuscript
Journal of Diabetes Research
Volume 2018 (2018), Article ID 5246976, 10 pages
https://doi.org/10.1155/2018/5246976
Research Article

Dipeptidyl Peptidase-4 Inhibitors and the Risk of Pancreatitis in Patients with Type 2 Diabetes Mellitus: A Population-Based Cohort Study

1Department of Medical Sciences, Ajou University Graduate School, Suwon, Republic of Korea
2Department of Internal Medicine, Incheon Medical Center, Incheon, Republic of Korea
3Korean Centers for Disease Control and Prevention, Ministry of Health and Welfare, Seoul, Republic of Korea
4Department of Endocrinology and Metabolism, Ajou University School of Medicine, Suwon, Republic of Korea

Correspondence should be addressed to Hae Jin Kim; rk.ca.uoja@miknij

Received 13 December 2017; Accepted 12 February 2018; Published 10 April 2018

Academic Editor: Pratibha V. Nerurkar

Copyright © 2018 Young-Gun Kim et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. O. J. Phung, J. M. Scholle, M. Talwar, and C. I. Coleman, “Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes,” JAMA, vol. 303, no. 14, pp. 1410–1418, 2010. View at Publisher · View at Google Scholar · View at Scopus
  2. E. Raschi, C. Piccinni, E. Poluzzi, G. Marchesini, and F. De Ponti, “The association of pancreatitis with antidiabetic drug use: gaining insight through the FDA pharmacovigilance database,” Acta Diabetologica, vol. 50, no. 4, pp. 569–577, 2013. View at Publisher · View at Google Scholar · View at Scopus
  3. S. J. Sankaran, A. Y. Xiao, L. M. Wu, J. A. Windsor, C. E. Forsmark, and M. S. Petrov, “Frequency of progression from acute to chronic pancreatitis and risk factors: a meta-analysis,” Gastroenterology, vol. 149, no. 6, pp. 1490–1500.e1, 2015. View at Publisher · View at Google Scholar · View at Scopus
  4. L. Azoulay, K. B. Filion, R. W. Platt et al., “Association between incretin-based drugs and the risk of acute pancreatitis,” JAMA Internal Medicine, vol. 176, no. 10, pp. 1464–1473, 2016. View at Publisher · View at Google Scholar · View at Scopus
  5. Y. J. Lai, H. Y. Hu, H. H. Chen, and P. Chou, “Dipeptidyl peptidase-4 inhibitors and the risk of acute pancreatitis in patients with type 2 diabetes in Taiwan: a population-based cohort study,” Medicine, vol. 94, no. 43, p. e1906, 2015. View at Publisher · View at Google Scholar · View at Scopus
  6. R. W. Thomsen, L. Pedersen, N. Moller, J. Kahlert, H. Beck-Nielsen, and H. T. Sorensen, “Incretin-based therapy and risk of acute pancreatitis: a nationwide population-based case-control study,” Diabetes Care, vol. 38, no. 6, pp. 1089–1098, 2015. View at Publisher · View at Google Scholar · View at Scopus
  7. L. M. Knapen, R. G. de Jong, J. H. Driessen et al., “Use of incretin agents and risk of acute and chronic pancreatitis: a population-based cohort study,” Diabetes, Obesity and Metabolism, vol. 19, no. 3, pp. 401–411, 2017. View at Publisher · View at Google Scholar · View at Scopus
  8. C. B. Giorda, E. Nada, B. Tartaglino, L. Marafetti, and R. Gnavi, “A systematic review of acute pancreatitis as an adverse event of type 2 diabetes drugs: from hard facts to a balanced position,” Diabetes, Obesity and Metabolism, vol. 16, no. 11, pp. 1041–1047, 2014. View at Publisher · View at Google Scholar · View at Scopus
  9. A. Gonzalez-Perez, R. G. Schlienger, and L. A. Rodriguez, “Acute pancreatitis in association with type 2 diabetes and antidiabetic drugs: a population-based cohort study,” Diabetes Care, vol. 33, no. 12, pp. 2580–2585, 2010. View at Publisher · View at Google Scholar · View at Scopus
  10. K. B. Blomgren, A. Sundstrom, G. Steineck, and B. E. Wiholm, “Obesity and treatment of diabetes with glyburide may both be risk factors for acute pancreatitis,” Diabetes Care, vol. 25, no. 2, pp. 298–302, 2002. View at Publisher · View at Google Scholar · View at Scopus
  11. L. Li, J. Shen, M. M. Bala et al., “Incretin treatment and risk of pancreatitis in patients with type 2 diabetes mellitus: systematic review and meta-analysis of randomised and non-randomised studies,” BMJ, vol. 348, no. apr15 2, article g2366, 2014. View at Publisher · View at Google Scholar · View at Scopus
  12. E. Bekiari, C. Rizava, E. Athanasiadou et al., “Systematic review and meta-analysis of vildagliptin for treatment of type 2 diabetes,” Endocrine, vol. 52, no. 3, pp. 458–480, 2016. View at Publisher · View at Google Scholar · View at Scopus
  13. M. B. Rehman, B. V. Tudrej, J. Soustre et al., “Efficacy and safety of DPP-4 inhibitors in patients with type 2 diabetes: meta-analysis of placebo-controlled randomized clinical trials,” Diabetes & Metabolism, vol. 43, no. 1, pp. 48–58, 2017. View at Publisher · View at Google Scholar · View at Scopus
  14. A. S. Abbas, H. M. Dehbi, and K. K. Ray, “Cardiovascular and non-cardiovascular safety of dipeptidyl peptidase-4 inhibition: a meta-analysis of randomized controlled cardiovascular outcome trials,” Diabetes, Obesity and Metabolism, vol. 18, no. 3, pp. 295–299, 2016. View at Publisher · View at Google Scholar · View at Scopus
  15. J. B. Buse, M. A. Bethel, J. B. Green et al., “Pancreatic safety of sitagliptin in the TECOS study,” Diabetes Care, vol. 40, no. 2, pp. 164–170, 2017. View at Publisher · View at Google Scholar · View at Scopus
  16. Z. Zhang, X. Chen, P. Lu et al., “Incretin-based agents in type 2 diabetic patients at cardiovascular risk: compare the effect of GLP-1 agonists and DPP-4 inhibitors on cardiovascular and pancreatic outcomes,” Cardiovascular Diabetology, vol. 16, no. 1, p. 31, 2017. View at Publisher · View at Google Scholar · View at Scopus
  17. Z. N. Sohani, L. Li, and X. Sun, “Incretin-based therapy: is the risk of pancreatitis driven by cardiovascular disease?” Diabetes Research and Clinical Practice, vol. 117, pp. 28–31, 2016. View at Publisher · View at Google Scholar · View at Scopus
  18. J. Lee, J. S. Lee, S. H. Park, S. A. Shin, and K. Kim, “Cohort profile: the National Health Insurance Service–National Sample Cohort (NHIS-NSC), South Korea,” International Journal of Epidemiology, vol. 46, no. 2, p. e15, 2017. View at Publisher · View at Google Scholar
  19. P. C. Butler, M. Elashoff, R. Elashoff, and E. A. Gale, “A critical analysis of the clinical use of incretin-based therapies: are the GLP-1 therapies safe?” Diabetes Care, vol. 36, no. 7, pp. 2118–2125, 2013. View at Publisher · View at Google Scholar · View at Scopus
  20. A. V. Matveyenko, S. Dry, H. I. Cox et al., “Beneficial endocrine but adverse exocrine effects of sitagliptin in the human islet amyloid polypeptide transgenic rat model of type 2 diabetes: interactions with metformin,” Diabetes, vol. 58, no. 7, pp. 1604–1615, 2009. View at Publisher · View at Google Scholar · View at Scopus
  21. D. J. Drucker and M. A. Nauck, “The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes,” The Lancet, vol. 368, no. 9548, pp. 1696–1705, 2006. View at Publisher · View at Google Scholar · View at Scopus
  22. R. Perfetti, J. Zhou, M. E. Doyle, and J. M. Egan, “Glucagon-like peptide-1 induces cell proliferation and pancreatic-duodenum homeobox-1 expression and increases endocrine cell mass in the pancreas of old, glucose-intolerant rats,” Endocrinology, vol. 141, no. 12, pp. 4600–4605, 2000. View at Publisher · View at Google Scholar
  23. M. A. Nauck, “A critical analysis of the clinical use of incretin-based therapies: the benefits by far outweigh the potential risks,” Diabetes Care, vol. 36, no. 7, pp. 2126–2132, 2013. View at Publisher · View at Google Scholar · View at Scopus
  24. S. S. Engel, D. E. Williams-Herman, G. T. Golm et al., “Sitagliptin: review of preclinical and clinical data regarding incidence of pancreatitis,” The International Journal of Clinical Practice, vol. 64, no. 7, pp. 984–990, 2010. View at Publisher · View at Google Scholar · View at Scopus
  25. M. M. Smits, L. Tonneijck, M. H. Muskiet et al., “Pancreatic effects of liraglutide or sitagliptin in overweight patients with type 2 diabetes: a 12-week randomized, placebo-controlled trial,” Diabetes Care, vol. 40, no. 3, pp. 301–308, 2017. View at Publisher · View at Google Scholar · View at Scopus
  26. J. L. Faillie, L. Azoulay, V. Patenaude, D. Hillaire-Buys, and S. Suissa, “Incretin based drugs and risk of acute pancreatitis in patients with type 2 diabetes: cohort study,” BMJ, vol. 348, no. apr24 1, article g2780, 2014. View at Publisher · View at Google Scholar · View at Scopus
  27. H. Y. Chang, C. F. Hsieh, S. Singh, W. Tang, Y. T. Chiang, and W. F. Huang, “Anti-diabetic therapies and the risk of acute pancreatitis: a nationwide retrospective cohort study from Taiwan,” Pharmacoepidemiology & Drug Safety, vol. 24, no. 6, pp. 567–575, 2015. View at Publisher · View at Google Scholar · View at Scopus
  28. C. H. Chang, J. W. Lin, S. T. Chen, M. S. Lai, L. M. Chuang, and Y. C. Chang, “Dipeptidyl peptidase-4 inhibitor use is not associated with acute pancreatitis in high-risk type 2 diabetic patients: a nationwide cohort study,” Medicine, vol. 95, no. 7, article e2603, 2016. View at Publisher · View at Google Scholar · View at Scopus
  29. M. o. H. a. W, “Korean Centers for Disease control and prevention,” Korea Health Statistics 2015: Korea National Health and Nutrition Examination Survey (KNHANES VI-3), Korea Centers for Disease Control and Prevention, Osong, South Korea, 2016. View at Google Scholar
  30. E. S. Johnson, B. A. Bartman, B. A. Briesacher et al., “The incident user design in comparative effectiveness research,” Pharmacoepidemiology & Drug Safety, vol. 22, no. 1, pp. 1–6, 2013. View at Publisher · View at Google Scholar · View at Scopus